Canada: Federal Court Of Appeal Confirms Ip Rights Not Categorically Immune From Competition Act Scrutiny - Apotex v. Eli Lilly and Shionogi

Last Updated: March 26 2006
Article by Andrea Feltham

The Federal Court of Appeal's recent decision provides some needed judicial guidance on the interface between intellectual property and competition laws in Canada. The Court concluded that the assignment of a patent (which is expressly permitted by section 50(1) of the Patent Act1 may, as a matter of law, constitute an agreement to unduly lessen competition contrary to section 45 of the Competition Act2 where there is evidence that the assignment is something more than the mere exercise of an intellectual property right.


In 1995, Shionogi, a Japanese pharmaceutical manufacturer, assigned to Eli Lilly four process patents related to the manufacture of the drug cefaclor. At that time, Eli Lilly owned four other of its own patents also related to cefaclor. In 1997, Eli Lilly sued Apotex for infringement of the cefaclor patents. Apotex counterclaimed against Eli Lilly and added Shionogi as a party, alleging that the assignment of the patents constituted an agreement to unduly lessen competition contrary to section 45(1) of the Competition Act.3 Apotex claimed that by combining the two sets of patents through an assignment by Shionogi to Lilly, Lilly acquired a monopoly, not through its own patent protection, but by a negotiated agreement contrary to section 45. Eli Lilly and Shionogi brought motions for summary judgment to dismiss Apotex' section 45 counterclaim. The Trial Division of the Federal Court granted the summary judgment motions of Eli Lilly and Shionogi. Citing Molnlycke AB v. Kimberly-Clark of Canada Ltd. Et Al.4 (Molnlycke), the Court held that any lessening of competition resulted from Shionogi's assignment of patents to Eli Lilly. Since the right to assign was authorized by section 50 of the Patent Act, any lessening of competition following the exercise of the right to assign could not be undue.

Apotex appealed the decision. The appeal was allowed on the ground that Molnlycke only applied when the lessening of competition resulted from the assignment alone. The Court of Appeal noted that if there was evidence of something more than the mere exercise of patent rights, the Competition Act claim was not necessarily excluded. The matter was referred back to the Trial Division to address certain questions. The Trial Division confirmed the view that Molnlycke applied. The Court held that any lessening of competition resulted from the assignment alone since there was no agreement alleged or shown between Shionogi and Eli Lilly other than the assignment. Again, Apotex appealed. As a signal of the importance of the case to competition law and policy, the Commissioner of Competition was granted intervener status on the appeal.

The Court of Appeal's Decision

The Federal Court of Appeal decided in Apotex's favour, permitting its counterclaim to proceed, and holding that the assignment could constitute an agreement to lessen competition within the meaning of section 45(1). While an assignment of patent rights on its own is not a violation of section 45(1), the assignment of the four patents to Eli Lilly resulted in a virtual monopoly for Eli Lilly in the manufacture of bulk cefaclor due to Eli Lilly's existing ownership of other patents. The Court concluded that:

[36] . the Judge erred in law by holding that the assignment of patents is exempt from section 45 when, by reason of the assignee's existing ownership of other patents, the assignment transfers more market power than that inherent in the patents assigned.

Therefore, the assignment constituted an agreement that lessened competition within the meaning of section 45(1). The Court allowed the matter to proceed to trial on all other issues, except whether there was a lessening of competition as a result of the assignment.5 The Court did not find that the assignment violated section 45(1). At trial, Apotex will still have to establish all of the elements of the offence, including that the lessening of competition resulting from the assignment was "undue" and the amount of any actual loss or damage suffered by Apotex as a result of the assignment.

Application of Molnlycke

The Federal Court of Appeal rejected the argument of Eli Lilly and Shionogi that since the right to assign is one of the rights conferred on patentees by Parliament, any lessening of competition following the exercise of the right to assign cannot be undue. Eli Lilly and Shionogi cited Molnlycke as binding authority for this proposition.

The Court distinguished Molnlycke from the present case on the basis that Molnlycke dealt with the situation in which the only market power created by the assignment was that inherent in the patent assigned. The assignment in Molnlycke resulted in a different company holding the patent, but there was no change in the total number of patent holders before and after the assignment. In this case, something more than the mere exercise of patent rights affected competition in the cefaclor market. The assignment gave Eli Lilly increased power in the market for bulk cefaclor as a result of its existing ownership of related patents. The Court pointed to the existence of section 32 of the Competition Act as evidence that there was no legislative intent to support the conclusion that the granting and assignment of intellectual property rights in accordance with the Patent Act or other intellectual property legislation necessarily immunizes the intellectual property holder from scrutiny under Canada's competition laws. Section 32 provides the Federal Court with the power to make broad remedial orders where it finds that an intellectual property holder has unilaterally used its rights to prevent or lessen competition unduly (i.e., without the need for an agreement as in section 45). The Court, in this case, accepted Apotex' argument that section 50 of the Patent Act and section 45 of the Competition Act can be read harmoniously, and that while section 50 permits patents to be assigned, neither the holding in Molnlycke nor section 50 of the Patent Act exempt the assignor and assignee from the need to comply with the Competition Act.6

Intellectual Property Enforcement Guidelines

The Federal Court of Appeal considered that Apotex' argument was consistent with the Competition Bureau's Intellectual Property Enforcement Guidelines ("IPEGs"). The IPEGs contemplate that something more than the mere exercise of an intellectual property right is necessary in order to constitute a violation of any of the general provisions of the Competition Act (which include section 45). The Bureau applies the general provisions of the Competition Act when intellectual property rights form the basis of arrangements (which may include the transfer or license of such rights) and when competitive harm results from the arrangement and not just from the exercise of the intellectual property rights.

The IPEGs state, at section 4.2, that: "If an IP owner licenses, transfers or sells the IP to a firm or a group of firms that would have been actual or potential competitors without the arrangement, and if this arrangement creates, enhances or maintains market power, the Bureau may seek to challenge the arrangement under the appropriate section of the Competition Act."

Significance of the Decision

The decision of the Federal Court of Appeal makes it clear that assignments of patents, or other intellectual property rights, are not immune from application of the Competition Act. Where such assignments result in market power beyond that which is inherent in the intellectual property right being assigned, they may raise competition concerns. In particular, assignments of patents among competing holders of related patents may be subject to scrutiny.


1. R.S.C. 1985, c. P-4.

2. R.S.C. 1985, c. C-34. Section 45(1) makes it a criminal offence for parties to enter into agreements which lessen competition unduly.

3. Section 36 of the Competition Act provides a private right of action for parties to sue to recover loss or damage suffered as a result of conduct that is contrary to the criminal provisions of the Competition Act, including section 45.

4. 36 C.P.R. (3d) 493.

5. Because the Federal Court had already concluded that the agreement between Lilly and Shionogi had the effect of lessening competition, the Federal Court of Appeal stated, at paragraph 39, that the question for trial was whether the lessening was sufficiently significant as to be undue.

6. Although it was not an issue to be decided in this case, the Court noted, at paragraph 24, that an assignment pursuant to section 50 of the Patent Act which unduly lessens competition and potentially gives rise to criminal proceedings under section 45 and a claim for damages under section 36, may still be valid as between the assignor and assignee, even though section 45 may prevent the assignee from enforcing the rights assigned against certain third parties.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.